Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Ilaprazole not inferior to rabeprazole in treatment of duodenal ulcer

06 Oct 2019

The efficacy of ilaprazole 5 mg appears to be on a par with rabeprazole 10 mg in treating duodenal ulcer, a study has shown. In addition, there is a dose-effect relationship between 5- and 10-mg ilaprazole.

In this double-blind, parallel, randomized study, patients aged >18 years with at least one endoscopically confirmed active nonmalignant duodenal ulcer received either rabeprazole 10 mg or ilaprazole 5/10 mg for 4 weeks. Ulcer healing was characterized by resolution from active to scarring stage.

The investigators assessed symptoms relief using a graded score and evaluated the safety and tolerability of these study drugs based on clinical assessments.

In total, 390 patients completed the study. Duodenal ulcer was successfully healed in 75.38 percent of patients in the rabeprazole 10-mg group, 77.86 percent in the ilaprazole 5-mg group and 83.72 percent in the ilaprazole 10-mg group after 4 weeks of treatment.

The 4-week healing rate difference between rabeprazole 10 mg and ilaprazole 5 mg was 2.58 percent (95 percent CI, –7.79 percent to 12.74 percent), showing the noninferiority of the latter. In logistic regression analysis, ilaprazole 10 mg was superior to ilaprazole 5 mg at week 2 (odds ratio, 1.92, 1.02–3.59; p=0.04).

Eighty percent of patients became asymptomatic after treatment. All three drug groups showed comparable efficacy and safety profile at the dosages administered.

“Ilaprazole is a kind of benzimidazole proton-pump inhibitor, which was confirmed efficacious and safe in treatment of duodenal ulcer,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Aug 2019
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
20 Aug 2019
The combination of pravastatin and sorafenib does not appear to improve survival in patients with hepatocellular carcinoma (HCC), a recent study has shown.
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.